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Summary
Background Little information is available about the eﬀ ect of pneumococcal conjugate vaccines (PCVs) in low-income 
countries. We measured the eﬀ ect of these vaccines on invasive pneumococcal disease in The Gambia where the 
7-valent vaccine (PCV7) was introduced in August, 2009, followed by the 13-valent vaccine (PCV13) in May, 2011.
Methods We conducted population-based surveillance for invasive pneumococcal disease in individuals aged 
2 months and older who were residents of the Basse Health and Demographic Surveillance System (BHDSS) in the 
Upper River Region, The Gambia, using standardised criteria to identify and investigate patients. Surveillance was 
done between May, 2008, and December, 2014. We compared the incidence of invasive pneumococcal disease between 
baseline (May 12, 2008–May 11, 2010) and after the introduction of PCV13 (Jan 1, 2013–Dec 31, 2014), adjusting for 
changes in case ascertainment over time.
Findings We investigated 14 650 patients, in whom we identiﬁ ed 320 cases of invasive pneumococcal disease. 
Compared with baseline, after the introduction of the PCV programme, the incidence of invasive pneumococcal 
disease decreased by 55% (95% CI 30–71) in the 2–23 months age group, from 253 to 113 per 100 000 population. This 
decrease was due to an 82% (95% CI 64–91) reduction in serotypes covered by the PCV13 vaccine. In the 2–4 years age 
group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 25–75), from 113 to 49 cases per 
100 000, with a 68% (95% CI 39–83) reduction in PCV13 serotypes. The incidence of non-PCV13 serotypes in children 
aged 2–59 months increased by 47% (–21 to 275) from 28 to 41 per 100 000, with a broad range of serotypes. The 
incidence of non-pneumococcal bacteraemia varied little over time.
Interpretation The Gambian PCV programme reduced the incidence of invasive pneumococcal disease in children 
aged 2–59 months by around 55%. Further surveillance is needed to ascertain the maximum eﬀ ect of the vaccine in 
the 2–4 years and older age groups, and to monitor serotype replacement. Low-income and middle-income countries 
that introduce PCV13 can expect substantial reductions in invasive pneumococcal disease.
Funding GAVI’s Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), Bill & 
Melinda Gates Foundation, and the UK Medical Research Council.
Copyright © Mackenzie et al. Open Access article distributed under the terms of CC BY.
Introduction
In 2008, an estimated 541 000 children younger than 
5 years died from pneumococcal disease worldwide.1 
Africa accounted for 57% of these deaths.1 Pneumococcal 
conjugate vaccines (PCVs) have been eﬀ ective in high-
income countries, reducing the incidence of invasive 
pneumococcal disease in both vaccinated and 
unvaccinated individuals.2–4 53 low-income countries 
have now introduced PCV5 into their routine 
immunisation programmes and robust assessment of 
their eﬀ ect is a priority.
In South Africa, where the population has a high 
prevalence of HIV infection, the introduction of the 
7-valent PCV (PCV7) was associated with reduced rates of 
invasive pneumococcal disease in young children and 
adults.6 The Gambia has a high burden of pneumococcal 
disease and low HIV prevalence.7,8 A Gambian trial9 of a 
9-valent PCV (PCV9), which ended in 2004, showed 77% 
eﬃ  cacy against invasive pneumococcal disease caused by 
vaccine serotypes, 50% against invasive pneumococcal 
disease overall, 37% against radiological pneumonia, and 
16% against overall mortality. Based on these results, and 
WHO recommendations, the Government of The 
Gambia introduced PCV7 into the national expanded 
programme of immunisation (EPI) on Aug 19, 2009, with 
a schedule of three doses at ages 2, 3, and 4 months, co-
administered with the DTPw–HepB–Hib vaccine. In this 
study, we used standardised population-based 
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surveillance to measure the eﬀ ect of routine infant 
vaccination with PCV on invasive pneumococcal disease 
in The Gambia.
Methods
Study design and participants 
This population-based surveillance study was undertaken 
in Upper River Region, The Gambia, where the UK 
Medical Research Council has a ﬁ eld station in the town 
of Basse. Residents of the Basse Health and Demographic 
Surveillance System (BHDSS) are served by Basse Health 
Centre and ﬁ ve smaller health facilities (appendix p 16).
We conducted surveillance for all cases of suspected 
pneumonia, sepsis, and meningitis between May 12, 2008, 
and Dec 31, 2014. The surveillance population included all 
residents of the BHDSS aged 2 months or older. The 
population is enumerated every 4 months, with births, 
deaths, migrations, and vaccinations recorded. The 
estimated population in 2014 was 178 510, of whom  32 530 
(18%) were children younger than 5 years.
Children younger than 6 months who presented at 
maternal and child health clinics were eligible to receive 
all three doses of the vaccine, whereas older children who 
presented at the clinics were eligible to receive one dose. 
PCV7 was introduced on Aug 19, 2009, and replaced by 
PCV13 in May, 2011, without catch-up vaccination.
The study was approved by the Gambia Government–
MRC Joint Institutional Ethics Committee (number 1087) 
and the ethics committee of the London School 
of Hygiene & Tropical Medicine (London, UK). 
Participants or their guardians gave written, informed 
consent.
Procedures
The surveillance methods used in our population-based 
study have been described previously.10 In brief, nurses 
assessed all individuals who presented as an outpatient or 
who were admitted to one of the six health facilities in the 
study area (Basse, Gambissara, Demba Kunda, Fatoto, 
Garawol, and Koina). Enrolment involved standardised 
screening of patients for referral to a clinician in Basse. 
Clinicians used standardised criteria to identify patients 
with suspected pneumonia, sepsis, or meningitis, and 
requested blood culture, lumbar puncture, or chest 
radiography according to protocol (appendix pp 7–9, 17). 
Aspiration of pleural ﬂ uid of lung aspiration was 
performed for patients with a pleural eﬀ usion or dense 
peripheral consolidation radiologically. We deﬁ ned 
Research in context
Evidence before this study
We did a systematic literature search of observational studies of 
the impact of pneumococcal conjugate vaccines (PCVs) on 
PubMed, Embase, and Web of Science from Jan 1, 2008, to 
Oct 31, 2015. We searched PubMed using the Medical Subject 
Headings (MeSH) terms “pneumococcal vaccines”, “vaccines, 
conjugate”, “meningitis”, “sepsis”, and the (All Fields) terms 
“pneumococcal”, “conjugate vaccines”, “meningitis”, “sepsis”, 
“septic(a)emia”, “bacter(a)emia”, “invasive pneumococcal 
disease”, “impact”, and “eﬀ ectiveness”. For other data sources, 
we used the key search terms as above. We searched for 
population-based studies, published in English language only, 
of invasive pneumococcal disease that included at least 2 years 
of data following the introduction of PCV. After reviewing 
1504 articles, 33 met inclusion criteria; the impact of PCV7 was 
measured in 24 studies and that of PCV10 or PCV13 in 13. 
No published reports were available from low-income 
countries. Most papers reported laboratory data without 
ensuring consistency of procedures for screening and 
investigation of patients. They showed consistent evidence of 
an overall reduction in invasive pneumococcal disease in 
children after the introduction of PCV7 (around 50%) with 
non-vaccine-type disease increasing over time by around 180%. 
Smaller and more variable reductions (16–48%) occurred in 
older age groups. Reductions in invasive pneumococcal disease 
in children after the introduction of PCV10 or PCV13 were 
consistently around 60–70%, with two of six papers reporting 
increased non-vaccine type disease and variable reductions in all 
invasive pneumococcal disease in older age groups.
Added value of this study
Our study showed substantial relative and absolute reductions 
in invasive pneumococcal disease in young children 5 years after 
the introduction of PCV7 and 3 years following the introduction 
of PCV13. This study provides robust evidence of the eﬀ ect of 
PCV in a low-income country. Our ﬁ ndings are widely relevant 
because the study was conducted in a typical African 
population, where the PCV programme used a standard 
schedule without a catch-up campaign—as is (and will be) the 
case in almost all low-income and middle-income countries. 
The study showed that ongoing surveillance is needed to 
measure the maximum eﬀ ect of the vaccine in those older than 
2 years, wider herd protection eﬀ ects, vaccine impact against 
serotype 1, and to monitor serotype replacement. These data 
are valuable to countries that might need data from a 
low-income country to support their policy and ﬁ nancing for 
pneumococcal vaccination.
Implications of all available evidence
The routine use of PCV13, with a standard schedule and 
reasonable coverage, will substantially reduce the burden of 
invasive pneumococcal disease in low-income and 
middle-income countries, where the pneumococcal disease 
burden and associated deaths are highest. Persisting disease 
due to non-vaccine type pneumococci emphasises the 
importance of developing new vaccines. Robust data 
assessing the eﬀ ect of PCV in Africa are scarce and surveillance 
must continue in the few sites where high-quality data are 
being collected. 
See Online for appendix
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invasive pneumo coccal disease as suspected pneumonia, 
sepsis, or meningitis with isolation. Vaccine failure was 
deﬁ ned as invasive pneumococcal disease following two or 
more doses of PCV covering the homologous serotype, 
given more than 14 days before the event.11,12 Weight was 
recorded on a digital scale (TANITA, Arlington Heights, 
IL, USA) and height with a ShorrBoard (Weigh and 
Measure, Olney, MD, USA). Rapid malaria tests 
(ICT Diagnostics, Cape Town, South Africa) were done on 
all patients with suspected pneumonia, sepsis, or 
meningitis from August to December (the malaria 
transmission season) each year and in a 10% random 
sample from January to July each year. This random 
sample was chosen by random selection of the ﬁ nal digit 
of the patients’ surveillance identity number (0–9) and 
during the dry season any patient whose identity number 
ended in zero had a malaria test. Samples were not 
collected between Oct 5 and Nov 3, 2010, when the ﬁ eld 
station ﬂ ooded.
Blood, lung aspirate, cerebrospinal ﬂ uid, pleural ﬂ uid, 
and other microbiological samples were processed in 
Basse using conventional microbiological culture and 
identiﬁ cation techniques.13 S pneumoniae was identiﬁ ed 
by morphology and optochin sensitivity. All pneumo-
coccal isolates were conﬁ rmed at the WHO Regional 
Reference Laboratory (MRC Fajara, The Gambia), and 
serotyped with a latex agglutination assay using factor 
and group-speciﬁ c antisera (Statens Serum Institut, 
Copenhagen, Denmark). Serotypes 6A and 6B were 
diﬀ erentiated from 6C by PCR.14 Serotyping of 10% of 
isolates was repeated at the National Institute for 
Communicable Diseases in South Africa (Johannesburg, 
South Africa). The laboratories in Basse and Fajara 
submitted to external quality assurance throughout the 
study (UK National External Quality Assessment Service 
[Sheﬃ  eld, UK], the WHO Reference Laboratory in 
Denmark, and the Royal Australasian College of 
Pathologists [Sydney, Australia]).
Statistical analysis
The primary outcome of the study was the incidence of 
invasive pneumococcal disease, in four categories: overall 
invasive pneumococcal disease; invasive pneumococcal 
disease caused by PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 
23F, and cross-reactive 6A);15 invasive pneumococcal 
disease caused by serotypes in PCV13 but not PCV7 
(1, 3, 5, 7F, and 19A, excluding serotype 6A); and invasive 
pneumococcal disease caused by non-vaccine serotypes.
We calculated the incidence of invasive pneumococcal 
disease by dividing the number of cases by the 
mid-point population estimates from the BHDSS and 
multiplying by 100 000. Age groups were prespeciﬁ ed 
as 2–23 months, 2–4 years, 5–14 years, and 15 years and 
older (adults). To calculate the incidence in 2008, 
we extrapolated cases for the unobserved period 
Jan 1–May 11, 2008. We derived the number of 
unobserved cases in 2008 by multiplying the number of 
observed cases from May 12 to Dec 31, 2008, by the 
average ratio of cases before and after May 12 in each of 
the years 2009 and 2011–14. The unobserved cases 
were grouped using the pre-PCV age and serotype 
distribution from 2008–09. For the ﬂ ood period in 2010 
(Oct 5–Nov 3, 2010), we extrapolated cases using the 
number of observed cases in 2010 multiplied by the 
average ratio of cases during the same period in each of 
the years 2009 and 2011–14. We applied the age and 
serotype distribution of the observed cases in 2010 to 
the unobserved cases in 2010.
We corrected for age-speciﬁ c changes in the number of 
individuals eligible for investigation per unit population 
by adjusting the counts of annual invasive pneumococcal 
disease by age group, assuming the same serotype 
distribution as that of the observed cases each year. 
We adjusted annual age-speciﬁ c counts of invasive 
pneumococcal disease to the mean rate of enrolment of 
patients eligible for investigation.
We assessed the eﬀ ect of the PCV vaccination 
programme by calculating the ratio of the incidence of 
invasive pneumococcal disease in the last 2 years of 
surveillance (2013–14) compared with the baseline ﬁ rst 
2 years (May 12, 2008–May 11, 2010). We used the 
Poisson distribution to calculate incidence rate ratios 
(IRRs) and 95% CIs. The widths of the conﬁ dence 
intervals were inﬂ ated to allow for overdispersion 
found in the 2–23-month and 5–14-year age groups, 
estimated from a patient-level Poisson regression 
analysis of 2008–09 pre-PCV invasive pneumococcal 
Figure 1: Vaccine coverage
Coverage of two or more doses of (A) PCV7 and (B) PCV13, by age group over time.
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disease data. Statistical signiﬁ cance was set at a p value 
less than 0·05.
To investigate potential bias caused by temporal changes 
in health-care seeking, patient investigation, or con-
founding attributable to secular trends in epidemic 
serotypes, we did three a-priori stratiﬁ ed analyses, 
excluding: outpatients, cases identiﬁ ed by lung aspiration 
alone, and cases caused by serotypes 1 or 5 which exhibit 
temporal variation in prevalence. To assess the eﬀ ect of 
temporal trends in invasive bacterial disease, we analysed 
the incidence of non-pneumococcal bacteraemia, as a 
control condition, extrapolating case counts for missing 
periods in the same manner as for invasive pneumococcal 
disease. We also analysed temporal changes in the 
prevalence of contaminated blood cultures, malnutrition, 
and malaria in patients eligible for investigation.
We used Stata version 12.1 and MATLAB version 
R2015a for our analyses.
Role of the funding source
The study was funded by GAVI’s Pneumococcal vaccines 
Accelerated Development and Introduction Plan 
(PneumoADIP), the Bill & Melinda Gates Foundation, 
and the UK Medical Research Council. None of the 
funding sources had any role in collection, analysis, or 
interpretation of the data. The corresponding author had 
full access to all the data and was responsible for the ﬁ nal 
decision to submit for publication.
Results
Our analysis showed that coverage of two or more doses of 
pneumococcal conjugate vaccine before 12 months of age 
in children born in the last 6 months of 2013 (indicative of 
the 2013–14 period) was 94% (3151/3364). Although the 
ﬁ rst 2 years of surveillance (May 12, 2008–May 11, 2010) 
overlapped with the introduction of PCV7 (Aug 19, 2009), 
the coverage of at least two doses of PCV7 in children 
2–23 months of age reached only around 35% by April, 
2010 (ﬁ gure 1A) and coverage of one dose in children older 
than 6 months was only around 4%, indicating that PCV7 
had little potential eﬀ ect in the baseline period. The 
proportion of children aged 2–23 months who had received 
at least two doses of PCV13 reached a plateau of around 
73% in mid-2013 (ﬁ gure 1B). The proportion of 2–4-year-old 
children who had received at least two doses of PCV13 
reached 50% by the end of 2014, and was still increasing 
(ﬁ gure 1B).
In total, 17 795 patients were screened for referral to a 
clinician (ﬁ gure 2). Surveillance performance was 
consistently high, including the annual proportion of 
patients referred who were clinically assessed (98–99%), 
the annual proportion who had microbiological 
investigation when indicated (90–97%), and the proportion 
of invasive pneumococcal disease cases with serotyping 
results (316/320 [99%]). The proportion of patients who 
had a lung aspiration was roughly 1% in the baseline and 
2013–14 periods, and 6% in 2010 and 2011 (appendix p 18).
We identiﬁ ed 320 cases of invasive pneumococcal 
disease (table 1). Pneumonia was suspected in 212 (66%) 
of these 320 cases, sepsis in 70 (22%), and meningitis in 
38 (12%). 28 (9%) patients died, with a 15% (12/81) 
mortality rate in the ﬁ rst year of life. Children aged 
2–11 months were more likely to have invasive 
pneumococcal disease caused by non-vaccine serotypes 
than were those aged 1–4 years (51/79 [65%] vs 33/160 
[21%], p<0·0009). There were no signiﬁ cant diﬀ erences 
Figure 2: Study proﬁ le during the observation period 
May 12, 2008–Dec 31, 2014
BHDSS=Basse Health and Demographic Surveillance System.
BHDSS residents 
146 876 in 2008
178 510 in 2014
Non-BHDSS residents using 
BHDSS health facilities
231 not referred
146 declined referral
85 failed referral
17 795 patients presented to BHDSS 
health facilities and met criteria
for referral to clinician
17 564 assessed by clinician
15 863 met criteria for investigation
  489 age 0–60 days
 13 960 age 2–59 months
  1414 age 5 years and over
14 650 investigated
      9850 age 2–23 months
      3414 age 2–4 years
       807 age 5–14 years
       579 age ≥15 years
320 cases of invasive pneumococcal
disease
 152 age 2–23 months
  91 age 2–4 years
  37 age 5–14 years
  40 age ≥15 years
1701 excluded
643 resident outside BHDSS
1058 not suspected 
pneumonia, 
septicaemia, or 
meningitis 
1213 excluded
489 age 0–60 days
724 not investigated
14 330 negative for 
 Streptococcus pneumoniae
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in sex (p=0·790), nutritional status (p=0·090), or 
mortality (p=0·122) between vaccine and non-vaccine 
serotype cases.
Across all age groups, 111 cases of invasive 
pneumococcal disease were recorded in the baseline 
2 years (2008–10); 38 (34%) were PCV7 serotype, 
55 (50%) were PCV13-only serotype, and 21 (26%) were 
non-vaccine type (table 2). In the 2013–14 period, there 
were 67 cases of invasive pneumococcal disease across 
all age groups; 12 (18%) were PCV7 serotype, 26 (38%) 
were PCV13-only serotype, and 29 (44%) were 
non-vaccine type. After adjustment of case counts, there 
was a 55% (95% CI 30–71) reduction in the incidence of 
all invasive pneumococcal disease from baseline to 
2013–14 in children aged 2–23 months, from 253 cases 
per 100 000 population to 113 cases per 100 000 (table 2, 
ﬁ gure 3). The incidence of invasive pneumococcal 
disease also fell by 56% (95% CI 25–75) in children aged 
2–4 years, from 113 to 49 cases per 100 000. In children 
aged 5–14 years, there was a non-signiﬁ cant reduction of 
invasive pneumococcal disease of 16% (95% CI –125 to 
69). The incidence in adults (aged ≥15 years) also fell, 
albeit non-signiﬁ cantly, by 59% (95% CI –3 to 84), from 
nine to four cases per 100 000.
In the 2–23 months age group, PCV7-type invasive 
pneumococcal disease fell by 83% (95% CI 57–93), from 
a baseline of 122 cases per 100 000 to 21 per 100 000 in 
2013–14; PCV13-type invasive pneumococcal disease fell 
by 82% (64–91), from 195 to 35 cases per 100 000; and 
PCV13-only type invasive pneumococcal disease also 
decreased by 82% (44–94), from 78 to 14 cases per 
100 000. Analysis restricted to the 6–23 months age 
group, with vaccine coverage higher than 80% (appendix 
p 19), is shown in appendix p 10. Smaller reductions 
occurred in 2–4-year-old children: PCV7-type invasive 
pneumococcal disease fell by 74% (95% CI 26–91) from 
44 to 11 cases per 100 000, PCV13-type disease fell by 68% 
(39–83) from 99 to 31 cases per 100 000, and PCV13 only-
type disease fell by 62% (15–83) from 58 to 22 per 100 000 
(table 2, ﬁ gure 3). There was no evidence of a reduction 
in PCV13 or PCV13-only-type invasive pneumococcal 
disease in the 5–14-year-old age group. In adults (aged 
≥15 years), there were some reductions in the incidence 
of PCV13-type invasive pneumococcal disease (50% 
[95% CI –32 to 81]) and PCV13-only-type invasive 
pneumococcal disease (48% [–39 to 80]), although these 
decreases were not signiﬁ cant.
We noted a non-signiﬁ cant increase of 48% (95% CI 
–30 to 213) in non-vaccine-type invasive pneumococcal 
disease in the 2–23 months age group, from 49 to 75 cases 
per 100 000, and of 27% (95% CI –61 to 313) in 2–4-year-olds. 
Overall, non-vaccine-type invasive pneumococcal disease 
increased by 47% (–21 to 175) in infants aged 2–59 months.
The estimates of the eﬀ ect of PCVs were unchanged in 
stratiﬁ ed analyses that excluded outpatients and cases 
detected only by lung aspiration (appendix pp 11–12). 
When cases caused by serotypes 1 or 5 were excluded, the 
eﬀ ect of vaccine against PCV13 serotypes was unchanged 
(appendix p 13). The incidence of the control condition of 
non-pneumococcal bacteraemia did not change between 
the baseline years and the 2013–14 period (appendix 
pp 14, 20).
The prevalence of malaria in patients aged 2–59 months 
and those aged 5 years and older, who were eligible for 
investigation, ﬂ uctuated between 5% and 17%, and 10% 
and 24% respectively, throughout the study period, with 
no signiﬁ cant diﬀ erence in prevalence between baseline 
and 2013–14 (appendix pp 21–22). Throughout the study, 
in children eligible for investigation, the prevalence 
of malnutrition remained stable at around 14% 
(appendix p 23), as was the prevalence of blood culture 
contamination at around 7% (appendix p 24).
In terms of serotype-speciﬁ c changes, the eﬀ ect of 
PCV7 vaccination in the 2–59-month age group was 
evident from 2011 onwards, with reduced cases of 
serotypes 6A and 14 (ﬁ gure 4A). Cases of serotype 5 
were reduced in 2013–14 (ﬁ gure 4B). 15 diﬀ erent 
serotypes contributed to the increase in non-vaccine-
type invasive pneumococcal disease in 2014 (ﬁ gure 4C). 
All invasive 
pneumococcal 
disease (n=320)
PCV7-type 
disease (n=69)*
PCV13-type 
disease only 
(n=158)*
Non-vaccine-
type disease 
(n=95)*
Age group
2–11 months 81 (25%) 15 (22%) 13 (8%) 51 (54%)
12–23 months 71 (22%) 23 (33%) 32 (20%) 17 (18%)
2–4 years 91 (29%) 25 (37%) 51 (33%) 16 (17%)
5–14 years 37 (12%) 3 (4%) 30 (19%) 4 (4%)
≥15 years 40 (13%) 3 (4%) 32 (20%) 7 (7%)
Sex
Male patients 194 (61%) 40 (58%) 99 (62%) 55 (58%)
Female patients 126 (39%) 29 (42%) 59 (38%) 40 (42%)
Diagnostic category†
Meningitis 38 (12%) 11 (16%) 10 (6%) 17 (18%)
Sepsis 70 (22%) 8 (12%) 29 (18%) 32 (34%)
Pneumonia 212 (66%) 50 (72%) 119 (76%) 46 (48%)
Pathology
Proven meningitis 23 (7%) 8 (12%) 3 (2%) 12 (13%)
Non-meningitis 297 (93%) 61 (88%) 155 (98%) 83 (87%)
Weight-for-height Z score <–3 
(age 2–59 months)
39/243 (16%) 13/63 (21%) 10/96 (10%) 16/84 (19%)
Treated as inpatient 291 (91%) 63 (91%) 146 (92%) 84 (88%)
Mortality 28 (9%) 7 (10%) 9 (6%) 13 (14%)
Proven meningitis 8 (3%) 4 (6%) 0 4 (4%)
Non-meningitis 20 (6%) 3 (4%) 9 (6%) 9 (10%)
PCV7=serotypes covered by the 7-valent pneumococcal conjugate vaccine: 4, 6B, 9V, 14, 18C, 19F, 23F, and cross-reactive 
6A. PCV13 only=serotypes covered only by the 13-valent pneumococcal conjugate vaccine: 1, 3, 5, 7F, and 19A. 
Non-vaccine type=serotypes not covered by PCV13. *The number of episodes of PCV7, PCV13 only, and non-vaccine type 
invasive pneumococcal disease do not add up to 320 cases; in six cases two diﬀ erent serotypes were detected in diﬀ erent 
samples and in four cases the isolate could not be serotyped. †Categories of surveillance diagnosis (appendix p 8) are 
mutually exclusive and ranked by severity; meningitis is the most severe, then sepsis, and then pneumonia.
Table 1: Characteristics of cases of invasive pneumococcal disease between May 12, 2008, and 
Dec 31, 2014, stratiﬁ ed by serotype 
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In the 5 years and older age group, a peak number of 
serotype 5 cases occurred in 2010, with one case detected 
in 2013 and one in 2014 (ﬁ gure 4D). The number of 
serotype 1 episodes in 2014 was similar to that reported 
in earlier years of surveillance (ﬁ gure 4D). 17 episodes of 
invasive pneumococcal disease were associated with 
vaccine failure; two each for serotypes 1, 6A, 19A, and 
19F; four for 23F; and ﬁ ve for serotype 14. Four children 
with vaccine failure were severely malnourished 
(appendix p 15).
Discussion
Population-based surveillance for almost 7 years in 
The Gambia has shown that, in the 2–23 months age 
group, following the introduction of PCVs into the EPI, 
there was an 82% reduction in invasive pneumococcal 
disease caused by PCV13 serotypes and a 55% 
reduction in all invasive pneumococcal disease. In the 
2–4 years age group, there was a 68% reduction in 
invasive pneumococcal disease caused by PCV13 
serotypes and a 56% reduction in all types of invasive 
pneumococcal disease.
Our ﬁ ndings are similar to those reported in other 
settings soon after implementation of PCV. Estimates 
of the eﬀ ect of PCV7 on all invasive pneumococcal 
disease in children younger than 2 years have varied 
between 56% in England and Wales16 and 69% in USA15 
and South Africa,6 with a somewhat greater eﬀ ect 
associated with PCV10 or PCV13 (62% in Oxford in the 
UK,17 71% in Denmark,18 78% in England and Wales,4 
and 80% in Finland).19 Our study might have 
underestimated vaccine impact in the 2–23 months age 
group because of the possible eﬀ ect of PCV7 in our 
baseline period and the fact that the proportion of 
children with at least two doses of this vaccine had not 
peaked by the beginning of 2013. The 56% reduction in 
May, 2008–
April, 2010 
adjusted 
(crude) cases
May, 2008–April, 
2010 adjusted 
(crude) incidence 
per 100 000 
population
2013–14 
adjusted 
(crude) cases
2013–14 
adjusted (crude) 
incidence per 
100 000 
population
Crude incidence rate 
ratio 2013–14 vs May, 
2008–April, 2010 
(95% CI)
Adjusted incidence 
rate ratio 2013–14 vs 
May, 2008–April, 
2010 (95% CI)
Age 2–23 months
All 55 (48) 253 (220) 32 (32) 113 (114) 0·52 (0·33–0·82) 0·45 (0·29–0·70)
PCV7 27 (23) 122 (106) 6 (6) 21 (21) 0·21 (0·08–0·51) 0·17 (0·07–0·43)
PCV13 43 (37) 195 (170) 10 (10) 35 (36) 0·21 (0·10–0·43) 0·18 (0·09–0·36)
PCV13 only 17 (15) 78 (69) 4 (4) 14 (14) 0·21 (0·07–0·64) 0·18 (0·06–0·56)
Non-vaccine type 11 (11) 49 (50) 21 (21) 75 (75) 1·48 (0·70–3·13) 1·48 (0·70–3·13)
Age 2–4 years
All 36 (33) 113 (102) 20 (22) 49 (55) 0·53 (0·31–0·91) 0·44 (0·25–0·75)
PCV7 14 (13) 44 (40) 5 (5) 11 (12) 0·31 (0·11–0·86) 0·26 (0·09–0·74)
PCV13 32 (29) 99 (90) 13 (14) 31 (35) 0·39 (0·20–0·73) 0·32 (0·17–0·61)
PCV13 only 19 (17) 58 (53) 9 (10) 22 (25) 0·47 (0·21–1·02) 0·38 (0·17–0·85)
Non-vaccine type 5 (4) 14 (12) 7 (8) 18 (20) 1·60 (0·48–5·30) 1·27 (0·39–4·13)
Age 5–14 years
All 10 (11) 12 (13) 10 (9) 10 (9) 0·69 (0·25–1·85) 0·84 (0·31–2·25)
PCV7 0 (0) Unspeciﬁ ed 1 (1) 1 (1) Unspeciﬁ ed Unspeciﬁ ed
PCV13 8 (9) 10 (11) 10 (9) 10 (9) 0·84 (0·30–2·38) 1·05 (0·37–2·99)
PCV13 only 8 (9) 10 (11) 9 (8) 9 (8) 0·75 (0·26–2·18) 0·95 (0·32–2·76)
Non-vaccine type 2 (2) 2 (2) 0 Unspeciﬁ ed Unspeciﬁ ed Unspeciﬁ ed
Age ≥15 years
All 14 (19) 9 (12) 7 (4) 4 (2) 0·18 (0·06–0·54) 0·41 (0·16–1·03)
PCV7 1 (2) 1 (1) 0 Unspeciﬁ ed Unspeciﬁ ed Unspeciﬁ ed
PCV13 11 (15) 7 (9) 7 (4) 4 (2) 0·23 (0·08–0·70) 0·50 (0·19–1·32)
PCV13 only 11 (14) 7 (9) 7 (4) 4 (2) 0·25 (0·08–0·76) 0·52 (0·20–1·39)
Non-vaccine type 3 (4) 2 (2) 0 Unspeciﬁ ed Unspeciﬁ ed Unspeciﬁ ed
PCV7=serotypes covered by PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F, and cross-reactive 6A. PCV13=serotypes covered by PCV13. PCV13 only=serotypes covered by PCV13 but not 
PCV7: 1, 3, 5, 7F, and 19A. Non-vaccine type=serotypes not covered by PCV13. In the 2–23 months age group, in the baseline period there were 48 cases of invasive 
pneumococcal disease and 49 episodes of serotype-speciﬁ c invasive pneumococcal disease. In the 2–4 years age group, in the baseline period there were 33 cases of invasive 
pneumococcal disease and 34 episodes of serotype-speciﬁ c invasive pneumococcal disease, and in 2013–14 there were 22 cases of invasive pneumococcal disease and 
23 episodes of serotype-speciﬁ c invasive pneumococcal disease. In the ≥15 years age group, in the baseline period there were 19 cases of invasive pneumococcal disease and 
20 serotype-speciﬁ c episodes. Case counts are adjusted for trends in patients eligible for investigation and rounded to the nearest integer. 95% CIs were calculated taking into 
account overdispersed Poisson distributions in the 2–23 months and 5–14 years age groups.
Table 2: Crude and adjusted numbers of cases and incidence of invasive pneumococcal disease in the baseline period (May 12, 2008–May 11, 2010), and 
in the 2013–14 period post-vaccine introduction and incidence rate ratios, by age group and serotype
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Figure 3: Adjusted annual incidence of invasive pneumococcal disease from 2008 to 2014, by age group and serotype
(A) Children aged 2–23 months. (B) Children aged 2–4 years. (C) Children aged 5–14 years. (D) Adults aged ≥15 years. 320 cases of invasive pneumococcal disease 
occurred in total; in six there were two diﬀ erent serotypes detected in diﬀ erent samples and in four the isolate could not be serotyped. The adjustment corrects for 
trends in the enrolment of patients eligible for investigation.
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Figure 4: Annual counts of serotype-speciﬁ c invasive pneumococcal disease
(A) PCV7 serotypes in children aged 2–59 months. (B) PCV13-only serotypes in children aged 2–59 months. (C) Non-PCV13 serotypes in children aged 2–59 months. 
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11B, 12A, 15B, 18A, 20, 21, 22A, 25A, and 40. (D) All serotypes in individuals aged 5 years and older.
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invasive pneumococcal disease in the 2–4 years age 
group recorded in our study is less than the 75% 
reported in England and Wales,4,16 although our ﬁ nding 
is probably an underestimate.
Herd protection in unimmunised children and adults 
following the introduction of PCV has been documented 
in many settings.4,6,15,16–18 Consistent with these ﬁ ndings, 
we noted a trend towards reduced invasive pneumococcal 
disease in adults, but our ﬁ ndings should be interpreted 
with caution given the small numbers of cases. Data 
from Kiliﬁ , Kenya, suggest likely herd protection eﬀ ects 
of PCV10, since carriage of vaccine-type pneumococci in 
children and older individuals was reduced by two-thirds 
following an extensive catch-up campaign.20
We observed a 48% (95% CI –30 to 213) increase in 
non-PCV13 type invasive pneumococcal disease in the 
2–59 months age group, although this increase was not 
signiﬁ cant. Following the introduction of PCV7 in 
developed countries, non-vaccine-type invasive pneu mo-
 coccal disease increased by two to three fold, although 
this increase was largely caused by serotypes covered by 
the PCV13 vaccine.21 Non-vaccine-type invasive pneu-
mococcal disease has increased following the 
introduction of PCV13 in Denmark,18 and England and 
Wales,4 but such a change is not yet evident in the USA.22 
Several years of surveillance post-introduction of PCV13 
might be necessary to assess the full eﬀ ect.21
We recorded temporal changes in some serotypes that 
were probably independent of vaccine introduction. 
Serotype 5 peaked in all age groups in 2010, whereas an 
increase in serotype 12F disease occurred in children 
younger than 5 years in 2011 (ﬁ gure 4). Such temporal 
changes in serotypes, and the low numbers of cases, 
necessitate cautious interpretation of serotype-speciﬁ c 
results. The eﬀ ect of PCV13 against serotype 1 that has 
been reported in other settings4,6,23 was not yet evident in 
our study. Eﬀ ects against this important serotype might 
need further time for the coverage of PCV13 to increase 
in the 2–4 years age group in which serotype 1 is more 
prevalent than in the ﬁ rst 2 years of life. Continued 
surveillance is needed to conﬁ rm the eﬀ ect of 
vaccination against this serotype in our setting.
Our study has several strengths. All screening, clinical 
investigation criteria, case deﬁ nitions, and laboratory 
practices were standardised and applied consistently 
throughout the study.10 However, there were some 
limitations. After initial piloting, we did only 16 months 
of surveillance before the introduction of PCV7. 
However, the proportion of children who had received at 
least two doses of PCV7 remained low for several 
months after vaccine introduction, allowing a 2-year 
baseline period. Before and after studies are prone to 
bias and confounding caused by changes in factors 
apart from vaccination that aﬀ ect the detection and risk 
of pneumococcal disease in the population. Our analysis 
provided some reassurance in this regard, with 
adjustment for temporal changes in the rate of patient 
investigation, demonstration of a stable incidence of the 
control condition of non-pneumococcal bacteraemia, 
and no change in estimates in stratiﬁ ed analyses.
The eﬀ ect of vaccination that we observed in 
The Gambia resulted from a PCV programme using a 
standard schedule and an introduction with eﬀ ectively 
no catch-up campaign, which are the programmatic 
circumstances that exist in most low-income countries. 
Thus, our ﬁ ndings have important implications for 
EPI programmes in other low-income countries and 
provide reassurance for those that have already 
introduced PCV. Questions to answer going forward 
that make ongoing surveillance in The Gambia and a 
few other settings a high priority include measuring 
the maximum eﬀ ect in those older than 2 years, the 
extent of herd protection, the magnitude of serotype 
replacement, and the eﬀ ect on pneumonia. These data 
will provide crucial information regarding con-
siderations of alternative immunisation schedules and 
the need and prioritisation of modiﬁ ed conjugate 
vaccines and vaccines designed to prevent disease 
caused by all pneumococcal serotypes.
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